# The George Institute: Phase 3 study in Septic Shock (2200 participants)

**Score:** 70/100

| Field | Value |
|---|---|
| Sponsor | The George Institute |
| Sponsor type | Academic and hospital |
| Study | A Trial of Adjunctive Fludrocortisone (50mcg, 100mcg or Placebo) in Critically Ill Patients With Septic Shock Receiving Hydrocortisone, Evaluating Survival and Functional Recovery and the Influence of Transcriptomic Response |
| NCT ID | NCT07898462 |
| Phase | Phase 3 |
| Status | recruiting |
| Conditions | Septic Shock |
| Intervention types | drug |
| Target enrollment | 2200 |
| Site countries | Australia |
| Posted | 2026-10-27 |
| Planned start | 2026-10-16 |
| Event | Newly registered study |
| Event date | 2026-10-27 |

## Why this score
- Posted in the last two weeks.
- Phase 3: multi-site, larger budget.
- 2200 participants planned.

Source: ClinicalTrials.gov (U.S. National Library of Medicine) API v2 (https://clinicaltrials.gov/study/NCT07898462). Last refreshed: 2026-11-04T06:04:38.232Z.
From public ClinicalTrials.gov registrations. Sponsor and study level only: we never list investigators, contacts or participants. A registration describes a planned study and can change. Status changes are read from each study's current status, actual dates and latest posted update, not a full change history, so an update can be a correction rather than a new change. Verify on ClinicalTrials.gov.